Emergent Biosolutions (EBS) said Friday that it reached an agreement to resolve a pending class action through a $40 million settlement.
The class action was filed in 2021 by certain shareholders who purchased Emergent common shares between March 10, 2020, and Nov. 4, 2021, according to the statement.
Emergent Biosolutions said the settlement deal remains subject to court approval and does not include its admission of liability or wrongdoing.
Price: 7.60, Change: -0.03, Percent Change: -0.39
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.